Takedas GAMMAGARD LIQUID Approved by U.S. FDA for Adults with Chronic Inflammatory Demyelinating Polyneuropathy CIDP
Takeda TSE4502NYSETAK today announced that the U.S. Food and Drug Administration FDA has approved GAMMAGARD LIQUID Immune Globulin Infusion Human 10 solution as an intravenous immunoglobulin IVIG therapy to improve neuromuscular disability and impairment in adults with chronic inflammatory demyelinating polyneuropathy CIDP.
Source: businesswireindia.com